SCHEMBL28486756

SCHEMBL28486756

O=C(O)c1ccccc1Nc1ccncc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 9/20 0.59
PBRM1 Q86U86 1/20 0.57
TTR P02766 3/20 0.56
MEN1 O00255 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
PTGS2 P35354 2/20 0.56
AKR1C3 P42330 2/20 0.56
KMT2A Q03164 2/20 0.56
USP2 O75604 1/20 0.56
MT-CO2 P00403 1/20 0.56
LMNA P02545 1/20 0.56
PLA2G1B P04054 1/20 0.56
CYP1A2 P05177 1/20 0.56
PGR P06401 1/20 0.56
CYP3A4 P08684 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
AR P10275 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30615706 1.00 FTO (0.59) FTOPBRM1TTRMEN1ADORA3
SCHEMBL4249088 0.82 PBRM1 (0.75) FTOPBRM1TTRMEN1ADORA3
SCHEMBL30575470 0.82 PBRM1 (0.75) FTOPBRM1TTRMEN1ADORA3
SCHEMBL10144160 0.82 PTGS2 (0.59) FTOTTRMEN1ADORA3PTGS2
SCHEMBL28297347 0.80 PBRM1 (0.73) FTOPBRM1TTRMEN1ADORA3
SCHEMBL28487702 0.80 METTL3 (0.58) FTOKMT2ALMNAMAPTHPGD
SCHEMBL355549 0.78 FABP4 (0.80) PBRM1TTRMEN1ADORA3PTGS2
SCHEMBL30320327 0.78 FABP4 (0.80) PBRM1TTRMEN1ADORA3PTGS2
SCHEMBL15286534 0.78 KDM4C (0.57) FABP4AURKAKDM4DKDM4C
SCHEMBL693586 0.78 PBRM1 (0.56) FTOPBRM1TTRMEN1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111868037-B Fused cyclic urea derivatives as CRHR2 antagonists 拉夸里亚创药株式会社 2023-10-13 CN disclosed
CN-111868037-A Fused cyclic urea derivatives as CRHR2 antagonists 拉夸里亚创药株式会社 2020-10-30 CN disclosed